News & Press Releases

Hartmut van Lengerich Appointed as Chairman of Aphea.Bio's Strategic Advisory Board

Gent, Belgium, 17 January 2024 - Aphea.Bio, a leading agricultural biotechnology company, is pleased to announce the appointment of Hartmut van Lengerich as Chairman of its newly formed Strategic Advisory Board. With over 30 years of experience in global strategic and operational roles, Hartmut brings a wealth of expertise and knowledge to Aphea.Bio.

Hartmut van Lengerich is a highly accomplished agricultural economist and industry leader. He has held various key positions throughout his career, including serving as Bayer Crop Science's CEO for Canada, Global Head of Cereals, Head of Fungicides, and, most recently, as SVP for Portfolio and Asset Management for the Crop Protection Portfolio of Bayer AG, where he oversaw $13 billion in worldwide sales. His career has been driven by a commitment to identifying and addressing growers' real problems through science, along with a belief in the power of collaboration and industry partnerships to drive positive change in global agriculture.

As Chairman of Aphea.Bio's Strategic Advisory Board, Hartmut will provide invaluable strategic guidance and insights to the company's leadership team. His deep understanding of the industry, coupled with his global experience, will contribute significantly to Aphea.Bio's growth and success in developing sustainable agricultural solutions.

Commenting on the appointment, Isabel Vercauteren, CEO at Aphea.Bio, stated, "We are thrilled to have Hartmut van Lengerich as the Chairman of our Strategic Advisory Board. His exceptional track record and expertise in the agricultural industry will be instrumental in guiding Aphea.Bio's strategic direction and ensuring our continued innovation in sustainable agriculture. We look forward to working closely with Hartmut and benefiting from his strategic insights."

Hartmut van Lengerich, a German national, is currently a senior adviser to Boston Consulting Group, further contributing to the advancement of the agricultural sector. His appointment as Chairman of Aphea.Bio's Strategic Advisory Board reinforces the company's commitment to leveraging top-notch expertise in revolutionizing sustainable agriculture.

"It is an honor to be appointed as Chairman of Aphea.Bio's Strategic Advisory Board. This is an exciting time for the agricultural industry, with a growing need for sustainable solutions. Aphea.Bio's commitment to developing innovative biological solutions aligns perfectly with my own vision for the future of farming," said Hartmut van Lengerich. " The approach of Aphea.Bio towards innovation is in my view unique and will provide value to growers in supporting crop production systems in a more sustainable way. This is demanded from growers, channel-partners, regulators, the food chain, consumers and society. I am eager to work alongside Aphea.Bio's dynamic team and contribute to the development of groundbreaking technologies that will shape the future of agriculture."

Aphea.Bio's Strategic Advisory Board comprises esteemed individuals from diverse backgrounds, collectively driving the company's strategic roadmap and innovation agenda. Together, they will propel Aphea.Bio forward in achieving its goal of revolutionizing sustainable agriculture worldwide.

About Aphea.Bio

Aphea.Bio is a fully integrated microbial product development company dedicated to food security and ensuring a safe and healthy food chain and is providing novel, science-based solutions to build the agriculture of the future: sustainable, reliable, and profitable. Located in Gent, Belgium, we have a highly dedicated and qualified team of scientist and industry experts. Based on our unique high throughput APEX® R&D platform utilising the untapped microbial space, we have been able to build a broad biostimulant and biocontrol pipeline based on naturally occurring micro-organisms.

We believe that with a fresh and sincere spirit of innovation, result-driven science, and the courage to go off the beaten track, there is fertile ground to develop efficacious biological solutions to help complement or partially replace products in the major chemical indications. To learn more, visit or follow us on LinkedIn at

Aphea Bio
Charlotte Klank
Head of Regulatory Affairs | Communications
[email protected]

Data protection is important to us. You are receiving this publication on the legal basis of Article 6 para 1 lit. f GDPR ("legitimate interest"). However, if you do not wish to receive further information about Aphea.Bio, just send us a brief informal message and we will no longer process your details for this purpose. You can also find further details in our privacy statement.

Cautionary Statement Regarding Forward-Looking Statements

This document may contain forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. For Aphea.Bio, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals, new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation, intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity prices, single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information technology. Aphea.Bio assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

© Aphea.Bio, Technologiepark Zwijnaarde 21, 9052 Zwijnaarde.

Aphea.Bio Welcomes Hadyn Parry as Chairman of its Board: Propelling the company's vision for Sustainable Agriculture.

Aphea.Bio secures € 70 million Series C Funding, accelerating the company's commercialisation efforts

Aphea.Bio becomes a Certified B Corporation, demonstrating high standards of social and environmental impact

ΛCTIV by Aphea.Bio® launched in Poland

New biostimulant seed treatment set to boost wheat yields with reduced fertilizer use